NCI and FDA Perspective, PublicationsComparison of the Binding Parameters of Melanoma Cells of Antihuman High Molecular Weight-Melanoma Associated Antigen (HMW-MAA) Monoclonal Antibodies (mAB) and Syngeneic Anti-Anti-Idiotypic
NCI and FDA Perspective, PublicationsClinical Responses to Intralymphatic Whole-Cell Melanoma Vaccine Augmented by in Vitro Incubation with Alpha-Interferon
NCI and FDA Perspective, PublicationsClinical Trials of Idiotype-Specific Vaccine in B-Cell Lymphomas
NCI and FDA Perspective, PublicationsEnhancement of a Spontaneous Immune Response Against a B-Cell Lymphoma by Dendritic Cells Leads to Protection Against the Tumor
NCI and FDA Perspective, PublicationsA Potential Surrogate Marker of Efficacy for a Therapeutic Melanoma Vaccine
NCI and FDA Perspective, PublicationsAntiidiotype (Ab2) Vaccine Therapy for Cutaneous T-Cell Lumphoma
NCI and FDA Perspective, PublicationsIdentification and Characterization of a Colon Tumor-Associated Antigen
NCI and FDA Perspective, PublicationsSpecific Immunotherapy Using a Recombinant Vaccinia Virus Expressing Human Carcinoembryonic Antigen
NCI and FDA Perspective, PublicationsRandomized Study of Adjuvent Immunotherapy with Autologous Tumor Cells and BCG in Renal Cancer
NCI and FDA Perspective, PublicationsSpecific Immunotherapy of Colorectal Cacinoma with Newcastle-Disease Virus-Modified Autologous Tumor Cells Prepared from Resected Liver Metastasis
NCI and FDA Perspective, PublicationsPhase Ib Trial of a Synthetic B Human Chorionic Gonadotropin Vaccine in Patients with Metastatic Cancer
NCI and FDA Perspective, PublicationsPancarcinoma T/Tn Antigen Detects Human Carcinoma Long before Biopsy Does and Its Vaccine Prevents Breast Carcinoma Recurrence
NCI and FDA Perspective, PublicationsActive Specific Immunotherapy of Hadgkin’s Lymphoma by an Anti-Idiotype Vaccine against the Hodgkin-Associated CD30 Antigen
NCI and FDA Perspective, PublicationsTransfection of TGF-B Producing Tumors with IL-2 Elicits Tumor Rejection
